Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated wit…
Medical - Diagnostics & Research
US, Madison [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -29.53 | 1.64 | 2.32 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 64.83 | -45.71 | -129.97 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -1.08 | 17.18 | 17.37 | |
| Cash | -16.71 | 3.58 | 4.29 | |
| Capex | -7.08 | -0.21 | -0.19 | |
| Free Cash Flow | 244.09 | -0.66 | 0.19 | |
| Revenue | -2.12 | 3.50 | 3.57 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.16 | 0.73 | 0.73 | |
| Operating Margin | -59.58 | -0.17 | -0.10 | |
| ROA | -124.79 | -0.02 | < 0.005 | |
| ROE | -122.39 | -0.04 | -0.02 | |
| ROIC | -62.19 | -0.02 | -0.01 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of EXAS is permitted for members.
5
Growth
The "Growth Entry" for the Focus of EXAS is permitted for members.
6
Leverage & Liquidity